How do I transition a patient on 75 U of Humulin N (NPH insulin) to Tresiba (insulin degludec)?

Switching from Humulin N 75 Units to Tresiba

Start Tresiba at 60 units once daily (80% of the current NPH dose), administered at any time of day in adults or at the same time daily in pediatric patients. 1

Conversion Algorithm

Initial Dose Calculation

• Take 80% of the current NPH dose: 75 units × 0.80 = 60 units of Tresiba once daily 1
• This reduction accounts for Tresiba's longer duration of action (ultra-long-acting) and more consistent pharmacokinetics compared to NPH
• If the patient's A1C is <8% (<64 mmol/mol), consider reducing by an additional 4 units or 10% to minimize hypoglycemia risk 1

Timing Considerations

• Adults: Can inject Tresiba at any time of day (does not need to be the same time daily) 2
• Pediatric patients: Must inject at the same time every day 2
• This flexibility is a key advantage over NPH's strict twice-daily schedule

Titration Strategy

After the initial switch:

• Wait 3-4 days between dose adjustments 1
• Increase by 2 units every 3 days to reach fasting plasma glucose goal 1
• Monitor fasting glucose closely as the primary titration target
• For hypoglycemia without clear cause: reduce dose by 10-20% 1

Critical Safety Considerations

Hypoglycemia Risk

The 2025 ADA Standards of Care specifically recommend switching from NPH to a basal analog when patients develop hypoglycemia 1. Research supports this: switching to degludec reduces overall hypoglycemia by 54% and nocturnal hypoglycemia by 65% in type 2 diabetes 3. The ultra-long half-life of Tresiba (>42 hours) provides more stable coverage with less peak effect than NPH.

Monitoring Requirements

• Increase blood glucose monitoring frequency during the transition period 2
• Check fasting glucose daily for the first 1-2 weeks
• Monitor for hypoglycemia, especially if the patient had frequent lows on NPH
• Ensure at least 8 hours between doses if a dose is missed in adults 2

Common Pitfalls to Avoid

1. Never transfer Tresiba from the pen into a syringe - this causes overdosage and severe hypoglycemia 2
2. Do not perform unit-for-unit conversion - always reduce to 80% of NPH dose 1
3. Do not mix Tresiba with other insulins - it is designed for once-daily use only
4. Avoid same-site injections - rotate between thighs, upper arms, and abdomen to prevent lipodystrophy 2

Expected Outcomes

Real-world evidence demonstrates that switching to Tresiba typically results in:

• Improved glycemic control: A1C reduction of 0.3% on average 4
• Reduced insulin requirements: 11-16% lower basal insulin doses 4, 5
• Better treatment satisfaction and simplified regimen (once vs. twice daily) 3
• Lower hypoglycemia rates: 72% reduction in severe hypoglycemia in type 1 diabetes 3

Special Populations

For patients requiring <5 units daily: Use Tresiba U-100 vial rather than the pen 2

For patients with insulin resistance: May see up to 16% dose reduction after switch 4

For patients on twice-daily NPH: The 80% conversion rule applies to the total daily NPH dose, not each individual injection 1

The evidence strongly supports this conversion strategy, with the 2025 ADA guidelines providing clear algorithmic guidance 1 and multiple studies confirming safety and efficacy 6, 4, 5, 3.